



ACARIX TO PRESENT AT THE 2022 NORDIC AMERICAN LIFE SCIENCE CONFERENCE

Acarix, a leader acoustic and AI-based cardiac diagnostics announces that the company will present at the 7th Annual Nordic American Life Science Conference, the most comprehensive Nordic life science innovation gathering in the United States.

Taking place in New York City, December 7-8, 2022, the Nordic American Life Science Conference brings together investors, corporate development executives and industry partners to meet and learn about the most promising Nordic life science companies and investments.

"We are honored that Acarix has been selected as one of the most promising Nordic life science companies to be presented at this event. I am looking forward to providing an update on the company and the important transformation that we are embarking on, as well as taking part in discussions on how our acoustic AI-powered CADScor®System can help improve the assessment for the many millions of patients seeking medical care for stable chest pain in the US", says Helen Ljungdahl Round.

During the conference, Helen Ljungdahl Round, President & CEO of Acarix, will give a presentation and participate in the panel discussion *Nordic Healthtech: an emerging engine of innovation*.

Read more about the Annual Nordic American Life Science Conference here:
www.nordic-americanlifescience.com.

For more information contact:

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email helen.round@acarix.com

Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com.

05 December 2022 14:40:00 CET



Attachments

[Acarix to present at the 2022 Nordic American Life Science Conference](#)